Collaboration and license agreements - Narrative (Details) $ in Thousands	1 Months Ended						3 Months Ended		6 Months Ended		40 Months Ended
	Sep. 30, 2021 USD ($)	Aug. 31, 2021	Nov. 30, 2020 USD ($) target	Feb. 29, 2020 USD ($) protein target	Dec. 31, 2018 USD ($)	Mar. 31, 2017 USD ($) targetProtein	Jun. 30, 2022 USD ($) performanceObligation target	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) performanceObligation target	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized that was included in the contract liability at the beginning of the period							$ 12,122	$ 5,535	$ 18,488	$ 10,054
Transaction price allocated to performance obligation							$ 67,822		$ 67,822
Restated Roche Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional upfront consideration received					$ 40,000
Number of potential targets | target			5
Annual research plan payments receivables			$ 1,000
Annual research plan payments periods			3 years
Restated Roche Agreement | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Option exercise fees			$ 7,000
Restated Roche Agreement | Minimum | Research, development and commercial milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amount eligible to receive			260,000
Restated Roche Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Option exercise fees			12,000
Option exercise fees, through Phase 1 trials			20,000
Restated Roche Agreement | Maximum | Research, development and commercial milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amount eligible to receive			275,000
Restated Roche Agreement | Maximum | One-time sales-based payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amount eligible to receive			150,000
Restated Roche Agreement | Lead Series Identification Achievement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront fees			2,000
Restated Roche Agreement | Good Laboratory Practice (“GLP”) Toxicology (“Tox”) Study Phase
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront fees			$ 3,000
Biogen License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research agreement, period				54 months
Research agreement, additional period				4 years
Additional payment on extension of agreement				$ 62,500
Nonrefundable upfront payment				$ 45,000
Number of performance obligation | performanceObligation							1		1
Number of targets | performanceObligation							5		5
Number of additional targets | target									2
Biogen License Agreement | Research and development services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized that was included in the contract liability at the beginning of the period									$ 55,000
Transaction price allocated to performance obligation							$ 16,400		$ 16,400
Biogen License Agreement | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Written notice period for termination of agreement				90 days
Biogen License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of targeted protein degradation | protein				5
Additional targets for development | target				5
Biogen License Agreement | Maximum | Research and development milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment received				$ 35,000
Biogen License Agreement | Maximum | One-time sales-based payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment received				$ 26,000
Calico License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of performance obligation | performanceObligation							1		1
Number of targets | target							5		5
Research term						5 years
Research extend term		1 year
Amount payable for extend research term option	$ 1,000
Upfront payment											$ 5,000
Annual payments											$ 5,000
Initial contractual term on straight line basis									5 years
Additional transaction price allocated to performance obligation	$ 1,000
Contractual term	6 years
Calico License Agreement | Research and development services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized that was included in the contract liability at the beginning of the period									$ 13,000
Transaction price allocated to performance obligation							$ 1,600		1,600
Calico License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of target proteins | targetProtein						5
Calico License Agreement | Maximum | One-time sales-based payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment received						$ 65,000
Calico License Agreement | Maximum | Potential research, development and commercial milestone payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment received						$ 132,000
Roche Agreement, Biogen Agreement, and Calico Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Transaction price allocated to performance obligation							$ 47,300		$ 47,300